Diasorin has launched a new test to identify Covid-19 variants. The test is called Simplexa Sarscov-2 Variants Direct and serves to identify and distinguish four Sars-Cov-2 mutations associated with the variants of the virus currently in circulation, quickly and without the need for the RNA extraction process. This was announced by the Italian diagnostic company based in Saluggia in the province of Vercelli and listed in Business Square (you can see here the quotes in real time). The test – reads a note – makes it possible to simplify and accelerate the pre-selection process of positive samples that need further analysis, consequently maximizing the effectiveness of monitoring programs for the diffusion of Covid-19 variants. worrying.
Use for research
The test – it is explained – a exclusive use of research (Research Use Only – Ruo) and should not be used as a diagnostic test and allows to qualitatively differentiate in vitro the mutations N501Y, E484K, E484Q, and L452R directly from nasal and nasopharyngeal swabs of patients who tested positive for Covid-19. The new test involves the United States, where Diasorin is present with the subsidiary DiaSorin Molecular, which is based in California. The identification of potential variants of SARS-CoV-2 in the samples tested positive for Covid-19 – commented John Gerace, president of DiaSorin Molecular – assumes extreme relevance in the United States, as well as globally, in the activities of monitoring, mapping and contrast to the spread of virus variants.